Drop in PML With Tysabri Use in Sweden Likely Due to Risk Management Plan

Drop in PML With Tysabri Use in Sweden Likely Due to Risk Management Plan

287236

Drop in PML With Tysabri Use in Sweden Likely Due to Risk Management Plan

The number of cases of Tysabri (natalizumab) that are associated with progressive multifocal leukoencephalopathy (PML) — a serious brain infection — in multiple sclerosis (MS) patients living in Sweden fell between 2006 and 2018, a study shows. Notably, the data highlighted that this drop was likely due to the introduction of a risk management plan (RMP) in 2012 that advises switching Tysabri-treated patients at risk of PML to other highly effective disease-modifying therapies (DMTs). These…

You must be logged in to read/download the full post.